IL-23 antibody for inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with Crohn's disease or ulcerative colitis.
- You have not had any major bowel surgery (like removing part of the small or large intestine).
- You do not have active infections like tuberculosis, shingles, or cytomegalovirus.
- You have no history of cancer or lymphoma.
- You agree to use birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This trial tests a new treatment using modified immune cells (CAR-T cells) to reduce inflammation in people with moderate to severe inflammatory bowel disease (IBD) that hasn't improved with other advanced treatments.
This study looks at how safe and effective a new type of medicine, called IL-23 inhibitors, is for people with ulcerative colitis or Crohn's disease. If you're starting this treatment for the first time, this study may help us learn more about how well it works.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests a low dose of IL-2 to reduce inflammation and help control Crohn’s disease symptoms. It’s for people whose Crohn’s disease hasn’t responded to at least one standard treatment or who need steroids to stay under control.
Hear when a new Crohn's Disease and Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.